# An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis

> **NCT06764693** · — · RECRUITING · sponsor: **AbbVie** · enrollment: 1200 (estimated)

## Conditions studied

- Psoriatic Arthritis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06764693
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-31
- **Primary completion:** 2029-01
- **Final completion:** 2029-02
- **Target enrollment:** 1200 (ESTIMATED)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06764693

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06764693, "An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06764693. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*